Business Context and Reporting Period
Company: Ameren Corporation (AEE)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2022
Event: Amendment to Equity Distribution Sales Agreement to increase the authorized gross sales price under its at-the-market equity distribution program.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The filing focuses exclusively on capital structure adjustments regarding an equity distribution program.
Material Changes
- Program Increase: Ameren increased the aggregate gross sales price authorized under its at-the-market equity distribution program by $1,000,000,000.
- Remaining Capacity: Following the increase, Common Stock with an aggregate gross sales price of $1,000,199,028 remains available for issuance under the program.
- Counterparties: The program involves multiple sales agents and forward sellers/purchasers, including Barclays, BofA Securities, Goldman Sachs, J.P. Morgan, Mizuho, Morgan Stanley, MUFG, and Wells Fargo.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard execution of the equity distribution program. The filing includes an opinion of counsel regarding the legality of the Common Stock issuance.
Investor Verification Checklist
- Verify the total remaining authorized amount under the equity distribution program ($1,000,199,028).
- Review the original Equity Distribution Sales Agreement dated May 12, 2021, to understand the terms of the program.
- Monitor future filings for actual share issuances and proceeds generated under this expanded program.
- Confirm the list of sales agents and forward purchasers involved in the transaction.